La Jolla, Ca., USA - June 3, 2015, La Jolla, Ca., USA - Regulus Therapeutics, a biopharmaceutical company, announced that Kleanthis G. Xanthopoulos has resigned as president, CEO and a member of Regulus' board.
Article continues below
Mr. Xanthopoulos joined Regulus around its formation in 2007. Prior to that, he was a managing director of Enterprise Partners Venture Capital.
Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000.
Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York.
An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Sente Inc., Zosano Pharma, Inc., and is chairman of the board of directors of Apricus Biosciences.
Paul C. Grint, who previously served as Chief Medical Officer of Regulus, has been appointed as President and Chief Executive Officer and as a member of Regulus' Board of Directors.
Dr. Grint joined Regulus in June 2014 with over two decades of experience in biologics and small molecule development. Prior to joining Regulus, het was President of Cerexa, a wholly-owned subsidiary of Forest Laboratories, Inc., where he was responsible for the oversight of anti-infective product development.
Prior to that, Dr. Grint served as Senior Vice President of Research at Forest Research Institute, Chief Medical Officer at Kalypsys, and Senior Vice President and Chief Medical Officer at Zephyr Sciences, and he also served in similar executive level positions at Pfizer, IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation.
Dr. Grint received his bachelor’s degree from St. Mary’s Hospital in London and his medical degree from St. Bartholomew’s Hospital Medical College at the University of London.
Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or co-author of over fifty scientific publications.
Neil W. Gibson who has served as Chief Scientific Officer, will continue through June 30, 2015 at the company as President's Fellow.
Dr. Gibson joined Regulus in April 2011 with a proven track record of success in the pharmaceutical industry. Having over 17 years of drug development experience, including the direction of strategy for oncology discovery efforts at Pfizer, he brings significant pharmaceutical research and development experience to Regulus.
Dr. Gibson joined Regulus from the Oncology Research Unit at Pfizer, La Jolla, where he most recently held positions as chief scientific officer and oncology therapeutic area head. Dr. Gibson also held leadership roles on Pfizer’s Oncology Business Unit leadership team and global leadership team of Pfizer’s Pharmatherapeutics Organization.
Prior to his years at Pfizer, Dr. Gibson held positions at OSI Pharmaceuticals including chief scientific officer, senior director of cancer discovery and vice president of research. His industry experience has also included service as a director for cancer research in the Department of Cancer and Osteoporosis for Bayer.
Dr. Gibson has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. ■